Strides Founder Back As MD, Asserts Confidence In US As Company Exits Parts Of Europe
Exits Canada Too In ‘Strategy Of Scale’
Back as Strides managing director, founder Arun Kumar is confident of reversing a slide in profits via a recalibration strategy that saw the company exit Canada and a few European markets. Meanwhile, eyes are on the fallout of a CRO that serviced Strides apart from Sandoz, Teva and more getting caught in CHMP and FDA’s crosshairs.
You may also be interested in...
Formycon has become the latest firm to announce a new CEO, after similar moves at Orion and Strides. Meanwhile, Gedeon Richter has made management changes and a new director has joined Coherus.
With the Shanghai lockdown extended, Russian vessels blacklisted and oil prices fluctuating, global freight rates are expected to increase further. Apart from a direct hit, pharma manufacturers will also feel the ripple effect as prices of raw materials like APIs increase. Scrip spoke to Indian industry to gauge the impact.
The US FDA has objected to studies conducted by India-based contract research organizations Panexcell Clinical Lab and Synchron Research Services, because of data integrity concerns. The FDA has warned pharmaceutical companies sponsoring drug application approvals, that data generated by Panexcell and Synchron will be “unacceptable.”